Tumor Escape

• 

  Subject Areas on Research

  • A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. 
  • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. 
  • Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 
  • Autologous tumor rejection in humans: trimming the myths. 
  • Bispecific antibodies engage T cells for antitumor immunotherapy. 
  • CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer. 
  • Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. 
  • Gold nanoparticles-mediated photothermal therapy and immunotherapy. 
  • Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. 
  • Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation. 
  • Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. 
  • Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. 
  • Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. 
  • Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. 
  • Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. 
  • STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion. 
  • Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. 
  • The Evolving Modern Management of Brain Metastasis. 
  • The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. 
  • Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. 
  • cDNA arrays and the enigma of melanoma immune responsiveness. 
• 

  Keywords of People

  • Hanks, Brent A., Associate Professor of Medicine, Pharmacology & Cancer Biology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology